Abstract:Joshua W. Goldman ^ , Rajen J. Mody ^ Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA ^ ORCID: Joshua W. Goldman, 0000-0001-9469-2295; Rajen J. Mody, 0000-0001-5574-1779. Comment on: Attarbaschi A, Möricke A, Harrison CJ, et al . Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study. J Clin Oncol 2023;41:1404-22. Keywords: Acute lymphoblastic leukemia (ALL); KMT2A ; menin; mixed lineage leukemia ( MLL ) Submitted Nov 29, 2023. Accepted for publication Jan 26, 2024. Published online Feb 27, 2024. doi: 10.21037/tp-23-567 While the 5-year overall-survival rate for pediatric acute lymphoblastic leukemia (ALL) now exceeds 90%, unfavorable ALL subtypes face a far inferior prognosis (1,2). Event-free and overall survival of lysine methyltransferase 2A [ KMT2A , formerly mixed lineage leukemia ( MLL )]-rearranged ( KMT2A -r) ALL lag behind other high risk cytogenetics abnormalities (2,3). Rearrangements involving 11q23/ KMT2A occur in approximately 75% of infantile ALL, 5% of childhood ALL in non-neonates, and 18% of pediatric acute myeloid leukemia (AML), with different KMT2A fusion partners yielding varied but overall poor prognoses (2,4,5). With greater than 100 translocation partners, better characterization of each KMT2A rearrangement and its prognostic impact across the ALL landscape is essential to guiding the next generation of clinical trial development, especially since targeted therapy with menin inhibitors has entered into Phase I/II clinical trials (6,7). The recent report from Attarbaschi et al. confirms that childhood KMT2A -r ALL outcomes in patients treated on contemporary cytotoxic chemotherapy regimens remain unsatisfactory both with regard to event-free and overall survival (4). This patient cohort desperately requires novel treatment strategies, potentially with bispecific T-cell engager antibodies, chimeric antigen receptor T-cell therapy, and menin inhibitors. While induction failure in childhood KMT2A -r ALL was rare, achievement of negative end-of-induction (EOI) minimal residual disease (MRD) across the reported cohort lagged behind non KMT2A -r patients. A complete response (CR), defined as an M1 marrow, was observed in 93% of patients (4). However, of evaluable patients, only 56% were MRD negative at EOI at a threshold of <0.05%, indicating that a significant cohort of these patients was predicted to have a high relapse rate (4). This MRD cutoff notably is higher than currently used cutoffs for either flow or high throughput sequencing-based MRD, so even MRD-negative patients as presented may be MRD positive in current practice (8,9). B cell ALL (B-ALL) patients with the most common t(4;11)(q21;q23)/KMT2A::AFF1 rearrangement only were EOI MRD negative 51% of the time while MRD negativity for B-ALL patients with t(10;11)(p12;q23)/KMT2A::MLLT10 reached 75% (4). T cell ALL (T-ALL) patients, while smaller in number, faced even more varied rates of EOI MRD negativity as low as 17% (n=6) for t(9;11)(p21;q23)/KMT2A::MLLT3 patients and 71% (n=7) for t(6;11)(q27;q23)/KMT2A::MLLT4 patients (4). Five-year event-free survival (EFS) was 69% for the entire cohort, with sub-stratification by rearrangement partner hovering within 10% of the overall cohort with two notable exceptions. Five year EFS among two T-ALL cohorts demonstrates the variability for therapy response among KMT2A -r patients, with an EFS of 91% (n=34) for t(11;19)(q23,p13.3)/KMT2A::MLLT1 patients and only 42% (n=19) for t(9;11) patients (4). For comparison, KMT2A -r infants treated on Interfant-06 achieved CR1 91% of the time with 60% EOI MRD negative, and 85% of patients achieved an M1 marrow with 68% EOI MRD negative on the MLL-10 study (5,10,11). These recent studies highlight the difficulty in achieving a deep remission for KMT2A -r ALL patients and are even more sobering since neither chemotherapy intensification nor allogenic hematopoietic stem cell transplant improved outcomes (4,5). These outcomes additionally all are inferior to the overall disease-free survival reported among very high-risk patients on the most recent Children's Oncology Group (COG) high risk trial AALL1131 (12). Furthermore, the publication of this childhood ALL cohort validates the prognostic value of the most common KMT2A rearrangement partners as seen in both infantile ALL and pediatric AML (5,13-15). This impressive report from the Ponte-di-Legno Childhood ALL Working Group also must be balanced against contemporary ALL studies that incorporate frontline immunotherapy (4). The drastic improvement of 2 year EFS to 82% from 49% with the addition of blinatumomab to Interfant-06 ther -Abstract Truncated-

Is acute lymphoblastic leukemia with mature B-cell phenotype and KMT2A rearrangements a new entity? A systematic review and meta-analysis

Mixed Phenotype Acute Leukemia with PML-RARα Positive: a Case Report and Literature Review

Recent Developments and Evolving Therapeutic Strategies in KMT2A‐Rearranged Acute Leukemia

Comprehensive Immunophenotypic Study of Acute Myeloid Leukemia with KMT2A (MLL) Rearrangement in Adults: A Single‐institution Experience

Paediatric B lymphoblastic leukaemia with hyperdiploidy and a false-positive KMT2A fluorescence in situ hybridization result

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study

Optimized Cytogenetic Risk-Group Stratification of KMT2A-Rearranged Pediatric Acute Myeloid Leukemia

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A -rearranged leukemia

Further validation of poor prognosis for pediatric KMT2A-rearranged leukemia and the need for rapid integration of targeted therapies for these patients

Multilineage involvement in KMT2A‐rearranged B acute lymphoblastic leukaemia: cell‐of‐origin, biology, and clinical implications

Co-existence of KMT2A::SEPTIN6 Fusion and DIS3 Variant in a Pediatric Case with Acute Myeloid Leukemia: a Case Report and Literature Review

A rare <i>KMT2A::CBL</i> transcript in an acute monoblastic leukemia patient with an unfavorable outcome

Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma

A rare KMT2A::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome

Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature

Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should Be Regarded As AML

Molecular Aspects and Therapeutic Perspectives

Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements

Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ KMT2A

CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy

Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey